Efficient and well‑tolerated revolutionary new drugs
Pharmacotherapy is most commonly administered for metastasised prostate cancer, but it’s also used as an additional therapy for localised high risk cancer. Many new, effective drugs intended for the treatment of metastasised cancer have entered the market – they are all available at Docrates. The new drugs are also often suitable for the elderly, patients with multiple illnesses, and combination therapy. The new prostate cancer drugs are often both more effective and better tolerated than previous drugs, and may even work after prior medication has lost its effectiveness. The new medicines can be used to alleviate symptoms, slow down disease progression in the bones in particular, and increase lifetime – the aim is for the patient to be able to continue leading as normal a life as possible.
There are three main types of new drugs:
Drugs intended for the treatment of bone metastases
- Intravenously administered Radium‑223 (Xofigo) targets bone metastases.
Targeted hormonal therapy in the form of pills (secondary hormonal therapy)
- For example, abiraterone (Zytiga) and enzalutamide (XTandi)
- For example, intravenously administered cabazitaxel (Jevtana)